Information Provided By:
Fly News Breaks for March 8, 2016
CLDX
Mar 8, 2016 | 07:12 EDT
Brean Capital noted they removed Rintega from their Celldex model before the company announced they would discontinue their Phase 3 trial. The firm sees several upcoming catalysts in the second half of the year and believes shares can be valued substantially higher than the present value. Brean Capital reiterated its Buy rating and $24 price target on Celldex shares.
News For CLDX From the Last 2 Days
There are no results for your query CLDX